Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.82 |
| ▸ | RAF1 | P04049 | 2/20 | 0.82 |
| ▸ | LYN | P07948 | 2/20 | 0.82 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.82 |
| ▸ | EGFR | P00533 | 1/20 | 0.82 |
| ▸ | BRAF | P15056 | 1/20 | 0.82 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.82 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.82 |
| ▸ | AKT1 | P31749 | 1/20 | 0.82 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.76 |
| ▸ | SRC | P12931 | 11/20 | 0.60 |
| ▸ | GSK3A | P49840 | 10/20 | 0.49 |
| ▸ | SYK | P43405 | 10/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086488 | 0.93 | ABL1 (0.82) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6609488 | 0.93 | ABL1 (0.84) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL14376097 | 0.93 | ABL1 (0.84) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL13941124 | 0.93 | ABL1 (0.70) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4091655 | 0.93 | ABL1 (0.84) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6053406 | 0.92 | ABL1 (0.82) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6612361 | 0.91 | ABL1 (0.80) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6613374 | 0.91 | ABL1 (0.82) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4081446 | 0.91 | ABL1 (0.82) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4456684 | 0.91 | ABL1 (0.88) | ABL1RAF1LYNMAPK9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | MOSS NEIL | 2007-07-05 | — | — | US | claimed |
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | claimed |
| US-7211575-B2 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | claimed |
| EP-1690854-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | claimed |
| EP-1658060-A2 | METHODS OF TREATING COPD AND PULMONARY HYPERTENSION | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050148555-A1 | Methods of treating COPD and pulmonary hypertension | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | US | claimed |
| WO-2005018624-A2 | METHODS OF TREATING COPD AND PULMONARY HYPERTENSION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| EP-1466906-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | claimed |
| EP-1427412-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-06-16 | — | — | EP | claimed |
| US-6660732-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | claimed |
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | claimed |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2003022273-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| JP-2002539198-A | — | — | 2002-11-19 | — | — | JP | claimed |
| CN-1349509-A | Compounds as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMA (US) | 2002-05-15 | — | — | CN | claimed |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-05-09 | — | — | US | claimed |
| EP-1165516-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| US-20100016449-A1 | Formulations with Improved Bioavailability | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | US | disclosed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | TNF, IL2, IL1B | ABL1 2843/4885RAF1 2509/4885LYN 2746/4885 |
| US-20050148555-A1 | Methods of treating COPD and pulmonary hypertension | PTGIS, PTGS1, MAPKAPK5 | ABL1 2764/4885RAF1 663/4885LYN 3274/4885 |
| US-20100016449-A1 | Formulations with Improved Bioavailability | ABCG2, SLC10A2, SI | ABL1 4510/4885RAF1 4058/4885LYN 2991/4885 |
| US-20070123516-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | ABL1 719/4885RAF1 464/4885LYN 852/4885 |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | TNF, IL2, IL1B | ABL1 2843/4885RAF1 2509/4885LYN 2746/4885 |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | ABL1 3659/4885RAF1 2736/4885LYN 2351/4885 |
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | ABL1 719/4885RAF1 464/4885LYN 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.